📊 ASTH Key Takeaways
Is Astrana Health, Inc. (ASTH) a Good Investment?
Astrana demonstrates strong revenue growth of 56.4% YoY, but faces severe operational challenges with near-zero gross margins (0.1%) and net income declining 51.8% despite scaling revenues—a sign of deteriorating unit economics. High leverage (1.22x D/E) combined with weak interest coverage (1.8x) and profitability margins of just 1.5% create financial vulnerability if operational performance does not substantially improve.
Astrana Health is showing strong top-line momentum, with revenue up 56.4% year over year and positive free cash flow generation, which suggests the business is scaling and still converting earnings into cash. However, profitability quality is weak: net income declined, diluted EPS fell sharply, margins remain very thin, and leverage is meaningful, so the current fundamental profile looks mixed rather than clearly strong.
Astrana Health, Inc. Key Strengths (ASTH)
- Exceptional top-line growth of 56.4% YoY showing strong market demand
- Positive free cash flow of $64.1M and solid cash position of $478.4M provides financial cushion
- Operating cash flow remains healthy at $68.1M despite net income deterioration
- Revenue growth is very strong at 56.4% year over year, indicating expanding scale and demand.
- Liquidity appears adequate, with $429.47M in cash and 1.40x current and quick ratios.
- Cash generation is positive, with $114.60M in operating cash flow and $104.49M in free cash flow.
ASTH Stock Risks: Astrana Health, Inc. Investment Risks
- Gross margin of 0.1% is critically low and unsustainable; cost structure severely misaligned with revenue
- Net income declining 51.8% while revenue grows 56.4% indicates accelerating margin compression and poor scalability
- Interest coverage ratio of only 1.8x combined with 1.22x debt-to-equity leverage leaves minimal buffer for operational decline
- Profitability is thin, with just 2.5% operating margin and 0.7% net margin, leaving limited cushion if costs rise.
- Earnings quality is under pressure, with net income down 6.6% and diluted EPS down 48.9% year over year.
- Leverage is elevated, with $990.90M of long-term debt, 1.27x debt-to-equity, and only moderate 4.9x interest coverage.
Key Metrics to Watch
- Gross margin trajectory and cost of services improvements
- Operating margin sustainability amid continued revenue scaling
- Debt service coverage and debt reduction pace relative to operating cash flow
- Operating and net margin improvement as revenue growth scales
- Debt reduction and interest coverage trend
Astrana Health, Inc. (ASTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Astrana Health, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ASTH Profit Margin, ROE & Profitability Analysis
ASTH vs Services Sector: How Astrana Health, Inc. Compares
How Astrana Health, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Astrana Health, Inc. Stock Overvalued? ASTH Valuation Analysis 2026
Based on fundamental analysis, Astrana Health, Inc. shows some fundamental concerns relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Astrana Health, Inc. Balance Sheet: ASTH Debt, Cash & Liquidity
ASTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Astrana Health, Inc.'s revenue has grown significantly by 311% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.29 reflects profitable operations.
ASTH Revenue Growth, EPS Growth & YoY Performance
ASTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $478.7M | $373.0K | $0.01 |
| Q2 2025 | $486.3M | $9.4M | $0.19 |
| Q1 2025 | $404.4M | $6.7M | $0.14 |
| Q3 2024 | $348.2M | $16.1M | $0.33 |
| Q2 2024 | $348.2M | $13.2M | $0.28 |
| Q1 2024 | $337.2M | $13.1M | $0.28 |
| Q3 2023 | $317.0M | $22.1M | $0.47 |
| Q2 2023 | $269.7M | $12.0M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Astrana Health, Inc. Dividends, Buybacks & Capital Allocation
ASTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Astrana Health, Inc. (CIK: 0001083446)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASTH
What is the AI rating for ASTH?
Astrana Health, Inc. (ASTH) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASTH's key strengths?
Claude: Exceptional top-line growth of 56.4% YoY showing strong market demand. Positive free cash flow of $64.1M and solid cash position of $478.4M provides financial cushion. ChatGPT: Revenue growth is very strong at 56.4% year over year, indicating expanding scale and demand.. Liquidity appears adequate, with $429.47M in cash and 1.40x current and quick ratios..
What are the risks of investing in ASTH?
Claude: Gross margin of 0.1% is critically low and unsustainable; cost structure severely misaligned with revenue. Net income declining 51.8% while revenue grows 56.4% indicates accelerating margin compression and poor scalability. ChatGPT: Profitability is thin, with just 2.5% operating margin and 0.7% net margin, leaving limited cushion if costs rise.. Earnings quality is under pressure, with net income down 6.6% and diluted EPS down 48.9% year over year..
What is ASTH's revenue and growth?
Astrana Health, Inc. reported revenue of $965.1M.
Does ASTH pay dividends?
Astrana Health, Inc. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find ASTH SEC filings?
Official SEC filings for Astrana Health, Inc. (CIK: 0001083446) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASTH's EPS?
Astrana Health, Inc. has a diluted EPS of $0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ASTH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Astrana Health, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ASTH stock overvalued or undervalued?
Valuation metrics for ASTH: ROE of 1.8% (sector avg: 16%), net margin of 1.5% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is ASTH's AI grade for 2026?
Our dual AI analysis gives Astrana Health, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASTH's free cash flow?
Astrana Health, Inc.'s operating cash flow is $68.1M, with capital expenditures of $4.0M. FCF margin is 6.6%.
How does ASTH compare to other Services stocks?
Vs Services sector averages: Net margin 1.5% (avg: 10%), ROE 1.8% (avg: 16%), current ratio 1.35 (avg: 1.5).